Collaboration will focus on innovative treatments for patients with various respiratory diseases
Chiesi and Affibody have announced a new collaboration and licensing agreement. The partnership will use Affibody’s proprietary technology to develop and commercialize innovative treatments for respiratory diseases.
The companies will use this partnership to advance up to three programs based on Affibody molecules targeting respiratory diseases. Chiesi, on the other hand, will fund all development, discovery and commercialization worldwide in line with the company’s strategy of bringing treatments to people with respiratory diseases.
The relative small size of the affibody molecules, in addition to their robustness, allows for the unique attributes explored in this collaboration, such as broad lung distribution and sustained exposure, as seen in preclinical models. will be
The partnership also aims to go beyond therapy by focusing on a broader patient experience.
Meanwhile, Affibody is eligible to receive development, regulatory and commercial milestone payments of up to $214 million.
David Bejker, CEO of Affibody AB, said: We recognize and appreciate Chiesi’s tremendous commitment and expertise in developing inhaled medicines and believe this partnership will help maximize the value of inhaled Affibody molecules. “
Chiesi Group’s Global Head of Research and Development, Thomas Eichholtz, believes this collaboration can make a difference. “
He added: “Our collaboration with Affibody adds an important new modality to our research and development portfolio with particularly interesting properties for inhalation. We look forward to developing the
Under the terms of the agreement, Affibody retains the option to co-promote products in the Nordic region.
